NanoViricides (NYSE:NNVC) Stock Crosses Below 200-Day Moving Average – Here’s Why

Shares of NanoViricides, Inc. (NYSE:NNVC) passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.30 and traded as low as $1.2101. NanoViricides shares last traded at $1.23, with a volume of 171,037 shares.

NanoViricides Stock Down 8.9%

The business has a fifty day simple moving average of $1.34 and a 200-day simple moving average of $1.30. The firm has a market cap of $31.40 million, a P/E ratio of -1.71 and a beta of 1.82.

Institutional Investors Weigh In On NanoViricides

Several institutional investors and hedge funds have recently made changes to their positions in the company. Empowered Funds LLC bought a new stake in shares of NanoViricides during the third quarter valued at approximately $46,000. Miller Financial Services LLC lifted its position in NanoViricides by 19.6% in the 3rd quarter. Miller Financial Services LLC now owns 134,000 shares of the company’s stock valued at $174,000 after acquiring an additional 22,000 shares in the last quarter. BlackRock Inc. bought a new position in NanoViricides in the 2nd quarter valued at approximately $219,000. Finally, Connective Capital Management LLC bought a new position in NanoViricides in the 2nd quarter valued at approximately $256,000. Institutional investors own 10.30% of the company’s stock.

About NanoViricides

NanoViricides, Inc. (NYSE American: NNVC) is a biotechnology company focused on developing broad-spectrum antiviral therapeutics. Its proprietary nanoviricide platform is designed to create nanomedicines that mimic the cellular receptors used by viruses, with the goal of binding to viral particles, disabling them and facilitating their removal from the body. The company has developed drug candidates targeting a range of viral diseases, including herpesvirus infections such as shingles and other conditions for which existing treatments may be limited.